From the Journals
Dry Eye Across Autoimmune Diseases
-
By
-
March 13, 2026
-
3 min
By
March 13, 2026
Phase 3 POETYK trial results support FDA approval of deucravacitinib for adults with active PsA.
March 9, 2026
Conventional monitoring markers do not change before deaths in this predominantly mild cohort.
March 6, 2026
Comparative analysis across exposed workers, cancer controls, and healthy donors supports specificity.
March 5, 2026